Crescent Biopharma

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland. GlycoMimetics, Inc. acquired by Crescent BioPharma in an Reverse Merger, where GlycoMimetics changed its name to Crescent BioPharma, Inc.